Evidence map›Paper›PMID 42490769›Full record

ArticlebioRxiv : the preprint server for biology2026

Flow-Induced Yap/Taz Signaling Balances Endothelial and Hematopoietic Stem Cell Fates.

Wade W Sugden, Stephan George, Zachary C LeBlanc, Morgan T Walcheck, Eleanor Meader, Julia Goldstein, Elizabeth Molnar, Wandi Zhu, Rubul Mout, Christopher Li and 17 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Wade W SugdenStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA USA.ORCID 0000-0002-8907-7359
Stephan GeorgeStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA USA.
Zachary C LeBlancStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA USA.
Morgan T WalcheckStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA USA.
Eleanor MeaderStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA USA.
Julia GoldsteinStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA USA.
Elizabeth MolnarStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA USA.
Wandi ZhuDepartment of Medicine, Brigham and Women's Hospital, Boston, MA USA.
Rubul MoutStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA USA.
Christopher LiStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA USA.
Leah RadekeVersiti Blood Research Institute, Milwaukee, WI, USA.
Zoey YoungVersiti Blood Research Institute, Milwaukee, WI, USA.
Maria Gonzalez di TillioStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA USA.
Marcelo FalchettiStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA USA.
Mohamad A NajiaStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA USA.ORCID 0000-0002-2558-8846
Yang TangStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA USA.
Brittney D LoveStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA USA.
Ran JingStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA USA.
Allison M TompkinsStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA USA.
Olivia StockardStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA USA.
Caroline KubaczkaStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA USA.
Katharina KirchhofDepartment of Medicine, Huddinge, Karolinska Institute, Sweden.
Vanessa LundinDepartment of Medicine, Huddinge, Karolinska Institute, Sweden.
Calum A MacRaeDepartment of Medicine, Brigham and Women's Hospital, Boston, MA USA.
Thorsten M SchlaegerStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA USA.
George Q DaleyStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA USA.
Trista E NorthStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA USA.ORCID 0000-0003-1249-563X

Funding

Molecular Circuits in the Hematopoietic Stem Cell NicheRC2DK120535 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI COLLINS, JAMES J, DALEY, GEORGE Q · 2020 to 2024
$8.2M
Training CoreTL1DK143273 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI Anna Greka · 2024 to 2026
$4.2M
Biomechanical Activation of Yap Induces Hematopoietic Stem Cell ProductionR01HL152636 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI NORTH, TRISTA E. · 2020 to 2023
$2.2M
Mechanisms of Flow-driven Transcriptional Control of Hematopoietic Stem Cell Development by YAPK01DK129409 · NIDDK · VERSITI BLOOD HEALTH, INC. · PI SUGDEN, WADE WILLIAM · 2021 to 2025
$926k
NHLBI NIH HHS R01 HL152636NIDDK NIH HHS K01 DK129409NIDDK NIH HHS RC2 DK120535NIDDK NIH HHS TL1 DK143273
6 · The paper itself

Abstract

Mechanical forces from blood flow are essential for production of hematopoietic stem and progenitor cells (HSPCs) during embryogenesis, but the molecular mechanisms by which hemodynamic cues are sensed and orchestrate endothelial-to-hematopoietic (EHT) transition remain incompletely defined. We previously identified YAP mechanotransduction as a key integrator of physical forces with EHT. Here we show that hemodynamic forces can activate YAP signaling via the mechanoresponsive ion channel Piezo1 in human iPSC-derived hemogenic endothelium (HE) and zebrafish embryos. Investigation of the Piezo1/YAP axis revealed shared and unique roles of YAP and its paralogue TAZ in EHT. Mechanistically, we find a requirement for the Tead DNA-binding co-factor in YAP/TAZ-dependent control of HSPC number, and note that TAZ uniquely augments transcriptional output of the hematopoietic master regulator Runx1 via direct protein-protein interactions. By comprehensive scRNA-sequencing of YAP/TAZ gain-of-function (GOF) and yap-deficient cells from zebrafish, we reveal that YAP/TAZ promotes HSC production by positively regulating gene programs for hematopoietic self-renewal, cell cycle, and glycolysis-to-oxidative phosphorylation switching, while preventing reversion to endothelial identity. Importantly, comparison of GOF transcriptomes and functional analyses suggest decoupling of metabolic/proliferative and endothelial gene regulatory modules between YAP and TAZ: while either can functionally compensate for loss of the other in EHT, indiscriminate overactivation of TAZ enhances an endothelial program over pro-hematopoietic fate, ultimately blunting progression of HSPC production. Given that hemodynamic cues are integrated simultaneously by arterial and HE cells in embryonic vessels in which EHT occurs, these findings have strong implications for strategies designed to introduce biomechanical cues to in vitro hematopoietic differentiation systems to drive HSC production.

Identifiers

PMID42490769
PMCPMC13374368

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.